FDA advisory panel unanimously recommends Moderna's mRNA flu vaccine for older adults
By
ALEXX ALTMAN-DEVILBISS | The National News Desk
Summary
An FDA advisory panel unanimously recommended approval of Moderna's mRNA-based flu vaccine, mFlusiva, for older adults. The vaccine uses the same mRNA technology as COVID-19 vaccines. The FDA is expected to make a final decision by early August. Moderna is seeking approval for ages 50-64 and authorization for 65+ while further testing continues.
Source
bskyFDA advisory panel unanimously recommends Moderna's mRNA flu vaccine for older adultsbit.lyKey quotes
· 3 pulledA panel of independent advisers to the Food and Drug Administration (FDA) unanimously recommended that the agency approve Moderna's flu vaccine, called mFlusiva, for older adults.
The vaccine uses the same mRNA technology that was used in COVID-19 vaccines.
Experts say mRNA vaccines can b
You might also wanna read
FDA advisory panel unanimously votes to approve Moderna's mRNA flu vaccine after Trump appointee tried to block review
FDA independent advisors voted 9-0 to recommend approval of Moderna's mRNA seasonal flu vaccine (mRNA-1010), despite a Trump appointee at th
arstechnica.com·1d ago
FDA Issues Refusal-to-File Letter to Moderna for mRNA Influenza Vaccine
The article criticizes the FDA's recent actions under the new administration, particularly focusing on a Refusal-to-File (RTF) letter issued
marginalrevolution.com·4mo ago
Personalized mRNA Cancer Vaccine Shows 49% Risk Reduction at 5-Year Follow-up
Moderna and Merck report promising 5-year follow-up results for their personalized mRNA cancer vaccine combined with Keytruda immunotherapy.
arstechnica.com·4mo ago
Moderna's Post-Pandemic Crisis: From Vaccine Success to Corporate Challenges
The article examines Moderna's current crisis despite its success with the COVID-19 vaccine. After achieving a 95% effective vaccine and mas
statnews.com·7mo ago
Study Examines Association Between mRNA COVID-19 Vaccination and 4-Year All-Cause Mortality in French Adults Aged 18-59
This cohort study analyzes data from over 28 million French adults aged 18-59 to examine the association between mRNA COVID-19 vaccination a
jamanetwork.com·6mo ago
HHS Ends mRNA Vaccine Development Under BARDA Following Review
The U.S. Department of Health and Human Services (HHS) has announced the wind-down of its mRNA vaccine development activities under BARDA, i
hhs.gov·10mo agoComments
Sign in to join the conversation.
No comments yet. Be the first.